| abstract |
The present invention provides a novel physiological substrate of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), a novel QC effector, a method for screening the effector, the use of the effector, and modulation of QC-activity. It provides a pharmaceutical composition comprising the effector for the treatment of a disease that can be treated with. Preferably the composition further comprises an inhibitor of DP IV or DP IV-like enzyme for the treatment or alleviation of a disease that can be treated by modulation of QC- and DP IV-activity. |